The Company engages in the research and development of drugs and vaccines. Its most advanced product, Multikine, manufactured using the Company's proprietary cell culture technologies, is being developed for the treatment of cancer.


Updates from The Motley Fool

Latest updates on CEL-SCI from Fool.com.
One Biotech Stock to Avoid

Each week, Motley Fool editors cull a top stock idea from the pitches made on CAPS, The Motley Fo...



Stock Performance

View Interactive CVM Charts
Sponsored by

Key Data Points

Primary metrics and data points about CEL-SCI.
Current Price: $0.12
Prev Close: $0.12
Open: $0.12
Bid: $0.12
Ask: $0.12
Day's Range: $0.12 - $0.14
52wk Range: $0.10 - $0.66
Volume: 6,341,664
Avg Vol 1,118,785
Market Cap: $15M
P/E (ttm): -0.64
EPS (ttm): ($0.19)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about CEL-SCI.
CAPS Rating 1 out of 5
 
91 Outperform
19 Underperform
CAPS All Stars
 
12 Outperform
4 Underperform

How do you think CEL-SCI will perform against the market?



You pick for CEL-SCI is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Geert R. Kersten, CEO

100% Approve

Based on 1 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for CEL-SCI.

The Company engages in the research and development of drugs and vaccines. Its most advanced product, Multikine, manufactured using the Company's proprietary cell culture technologies, is being developed for the treatment of cancer.

  • Exchange: NYSEMKT
  • Sector: Healthcare
  • Industry: Drug Makers